Title: Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.
Journal: Journal of neural transmission (Vienna, Austria : 1996) 20100601
Title: A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
Journal: BMC clinical pharmacology 20090101
Title: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Journal: Drug metabolism and pharmacokinetics 20070401
Title: Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Journal: Journal of neural transmission. Supplementum 20070101
Title: Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205
Title: High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users.
Journal: Journal of analytical toxicology 20060501
Title: Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.
Journal: Journal of analytical toxicology 20030401
Title: Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage.
Journal: European journal of pharmacology 20030101
Title: Neuroprotection for Parkinson's disease: prospects and promises.
Journal: Annals of neurology 20030101
Title: Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Journal: Journal of medicinal chemistry 20021121
Title: Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.
Journal: Journal of analytical toxicology 20021001
Title: Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20020901
Title: Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Journal: European journal of clinical pharmacology 20020701
Title: Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.
Journal: Mechanisms of ageing and development 20020430
Title: CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Journal: European journal of clinical pharmacology 20010501
Title: Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice.
Journal: Experimental neurology 20010401
Title: Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Journal: European journal of clinical pharmacology 20010401
